Latest market price
99.18
-1.22-1.22%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -4.19 | Insider Own | — | Shs Outstand | 62.85M | Perf Week | 13.18% |
| Market Cap | 6.23B | Forward P/E | — | EPS next Y | -3.85 | Insider Trans | 4.68% | Shs Float | 57.48M | Perf Month | 0.73% |
| Enterprise Value | 6.20B | PEG | — | EPS next Q | -1.06 | Short Float | 14.79% | Perf Quarter | 149.01% | ||
| Income | -242.00M | P/S | — | EPS this Y | — | Short Ratio | 5.10 | Perf Half Y | 125.61% | ||
| Sales | 0.00 | P/B | 102.18 | EPS next Y | — | ROA | -94.23% | Short Interest | 8.50M | Perf YTD | 254.72% |
| Book/sh | 0.97 | P/C | 49.47 | EPS next 5Y | — | ROE | -273.23% | 52W High | 104.00 -4.63% | Perf Year | 423.93% |
| Cash/sh | 2.00 | P/FCF | — | EPS past 3/5Y | — | ROIC | -115.23% | 52W Low | 15.83 526.53% | Perf 3Y | 6984.29% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 6.33% 7.22% | Perf 5Y | 327.50% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 6.60 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.49 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 66.45 | Recom | 2.32 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.49 | EPS Q/Q | -1.94% | SMA20 | 7.79% | Beta | 1.76 | Target Price | 104.40 |
| Payout | 0.00% | Debt/Eq | 1.57 | Sales Q/Q | — | SMA50 | 55.64% | Rel Volume | 0.33 | Prev Close | 100.40 |
| Employees | 141 | LT Debt/Eq | 1.41 | Earnings | Nov 12 | SMA200 | 135.62% | Avg Volume | 1.73M | Price | 99.18 |
| IPO Date | Oct 04, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -9.78% — | Net Debt/EBITDA | — | Volume | 567,495 | Change | -1.22% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | HC Wainwright & Co. | Buy | $96 → $126 |
| Sep-30-26 | Reiterated | Goldman Sachs | Neutral | $36 → $103 |
| Sep-28-26 | Reiterated | Jefferies | Buy | $56 → $112 |
| Sep-28-26 | Reiterated | UBS | Buy | $80 → $120 |
| Sep-28-26 | Reiterated | HC Wainwright & Co. | Buy | $58 → $96 |
| Sep-24-26 | Resumed | Goldman Sachs | Neutral | $2.00 → $36 |
| May-11-26 | Upgrade | Chardan Capital | Neutral → Buy | $18 → $61 |
| Mar-27-26 | Reiterated | HC Wainwright & Co. | Buy | $38 → $58 |
| Mar-27-26 | Reiterated | UBS | Buy | $50 → $80 |
| Mar-26-26 | Reiterated | Jefferies | Buy | $39 → $56 |
Latest News· Times ET
Oct-28-26
Oct-20-26
Oct-19-26
Oct-16-26
Oct-16-2602:45AM
Oct-12-26
Oct-08-26
Oct-07-26
Oct-07-2607:00AM
Oct-02-26
Oct-02-2602:02PM
Oct-01-26
05:41AM
Sep-30-26
Sep-30-2608:05AM
Sep-29-26
06:34AM
Sep-28-26
Company
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 27 | 26 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | -27 | -26 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 46 | 52 | 34 | 71 | — | — | — | — | — | |
| Research and Development | 200 | 182 | 126 | 206 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | -26 | — | — | — | — | — | |
| Operating Income | -246 | -234 | -187 | -277 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | 4 | 11 | 17 | — | — | — | — | — | |
| Net Income Before Taxes | -242 | -230 | -176 | -260 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -242 | -230 | -176 | -260 | — | — | — | — | — | |
| Net Income From Continuing Operations | -242 | -230 | -176 | -260 | — | — | — | — | — | |
| Net Income | -242 | -230 | -176 | -260 | — | — | — | — | — | |
| EPS (Recurring) | -4.19 | -4.32 | -3.35 | -4.97 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.19 | -4.32 | -3.35 | -4.97 | — | — | — | — | — | |
| EPS (Diluted) | -4.19 | -4.32 | -3.35 | -4.97 | — | — | — | — | — | |
| EBITDA | -215 | -204 | -150 | -235 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 63 | 53 | 53 | 52 | — | — | — | — | — | |
| Market Capitalization | 6,248 | 1,482 | 527 | 158 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Yang Taiyin | Director | Oct 23 '26 | Option Exercise | 2.35 | 20,000 | 47,000 | 20,000 | Oct 26 |
| BORGESON JOHN A. | Chief Financial Officer | Oct 21 '26 | Sale | 90.01 | 30,000 | 2,700,322 | 211,930 | Oct 23 |
| BORGESON JOHN A. | Chief Financial Officer | Oct 21 '26 | Option Exercise | 2.49 | 30,000 | 74,700 | 241,930 | Oct 23 |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | Sep 29 '26 | Buy | 85.05 | 33,726 | 2,868,255 | 20,191,214 | Sep 30 |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | Sep 28 '26 | Buy | 80.77 | 1,908,029 | 154,118,141 | 20,159,386 | Sep 30 |
| PERLROTH VICTOR | Chairman and CEO | Sep 25 '26 | Option Exercise | 4.20 | 1,280,524 | 5,381,944 | 3,676,062 | Sep 29 |
| BORGESON JOHN A. | Chief Financial Officer | Jun 04 '26 | Option Exercise | 1.04 | 30,000 | 31,200 | 241,930 | Jun 05 |
| BORGESON JOHN A. | Chief Financial Officer | Jun 04 '26 | Sale | 34.10 | 30,000 | 1,023,009 | 211,930 | Jun 05 |
| BORGESON JOHN A. | Chief Financial Officer | Apr 15 '26 | Option Exercise | 1.04 | 28,614 | 29,759 | 211,930 | Apr 16 |
| BORGESON JOHN A. | Chief Financial Officer | Apr 02 '26 | Option Exercise | 1.04 | 30,000 | 31,200 | 213,316 | Apr 02 |
| BORGESON JOHN A. | Chief Financial Officer | Apr 02 '26 | Sale | 39.92 | 30,000 | 1,197,488 | 183,316 | Apr 02 |
| PERLROTH VICTOR | Chairman and CEO | Mar 25 '26 | Option Exercise | 1.04 | 300,000 | 312,000 | 2,395,538 | Mar 27 |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | Dec 18 '25 | Buy | 23.00 | 2,608,696 | 60,000,008 | 18,358,772 | Dec 19 |
| BORGESON JOHN A. | Officer | Jun 17 '25 | Sale | 3.65 | 723 | 2,640 | 183,316 | Jun 17 |
| BORGESON JOHN A. | Officer | Jun 15 '25 | Option Exercise | 0.00 | 1,875 | 0 | 184,039 | Jun 17 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.